There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Veracyte (VCYT – Research Report) and Irhythm Technologies (IRTC – Research Report) with bullish sentiments.
Veracyte (VCYT)
Needham analyst Michael Matson reiterated a Buy rating on Veracyte today and set a price target of $33.00. The company’s shares closed last Thursday at $24.34.
According to TipRanks.com, Matson is a 1-star analyst with an average return of
Veracyte has an analyst consensus of Moderate Buy, with a price target consensus of $34.00.
See the top stocks recommended by analysts >>
Irhythm Technologies (IRTC)
Needham analyst David Saxon reiterated a Buy rating on Irhythm Technologies today and set a price target of $137.00. The company’s shares closed last Thursday at $115.07.
According to TipRanks.com, Saxon is a 4-star analyst with an average return of
Irhythm Technologies has an analyst consensus of Strong Buy, with a price target consensus of $130.00, representing a 16.2% upside. In a report issued on February 16, J.P. Morgan also maintained a Buy rating on the stock with a $142.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VCYT:
